LAUSANNE, Switzerland, June 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company has made grants of options to purchase an aggregate of 109,800 of the Company's common shares to three new employees on June 3, 2024 (each, a "Grant"). The Grants were offered as material inducement to the employees' employment. The grants were approved by the Compensation Committee of the Company's Board of Directors pursuant to the Company's Inducement Plan to motivate and reward the recipients to perform at the highest levels and contribute significantly to the success of the Company. The Grants were made in reliance on the employment inducement exemption under the NYSE's Listed Company Manual Rule 303A.08. The Company is issuing this press release pursuant to Rule 303A.08. The Grants shall vest and become exercisable 25% on the first anniversary of the grant date, and 1/48th of the aggregate number of shares subject to the award on each monthly anniversary of the grant date thereafter, such that the entire award will be vested as of the fourth anniversary of the grant date, subject to continued employment with the Company.
瑞士洛桑，2024年6月3日（GLOBE NEWSWIRE）——ADC Therapeutics SA（紐約證券交易所代碼：ADCT）今天宣佈，公司已於2024年6月3日向三名新員工授予總共109,800股公司普通股的期權（每股均爲 “補助金”）。這些補助金是作爲對僱員就業的物質刺激而提供的。根據公司的激勵計劃，這些補助金由公司董事會薪酬委員會批准，旨在激勵和獎勵接受者保持最高水平，爲公司的成功做出重大貢獻。補助金是根據紐約證券交易所上市公司手冊第303A.08條規定的就業激勵豁免發放的。該公司根據第303A.08條發佈本新聞稿。獎勵應在授予日期的第一個週年紀念日歸屬並可行使25%，此後在授予日期的每個月週年紀念日歸屬並可行使獎勵股份總數的1/48，這樣，在繼續受僱於公司的情況下，全部獎勵將在授予日期的第四個週年紀念日歸屬。
